comprehensive -WSS

comprehensive

author：leisure time 2025-10-04 05:24:20 Page View：798

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Key Senate committee drafts bipartisan bill to stem drug shortages
Next article： After affirmative action ruling, medical educators look to 'holistic review'

leisure time

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Cancer researcher Catriona Jamieson is sending tumors into space

CatrionaJamieson,directoroftheSanfordStemCellInstituteattheUniversityofCalifornia,SanDiego,hassentst

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Cholera vaccine supply gets boost as demand surges globally

AnurseshowsacholeravaccineinGedaref,Sudan,duringavaccinationcampaign.Anewvaccine,calledEuvichol-S,wi

comprehensive

focus

leisure time

Cholera vaccine supply gets boost as demand surges globally